Magnesium supplements — glycinate, citrate, threonate, oxide and the evidence

Magnesium in the supplement aisle — and in the clinic

Magnesium is the mineral of the moment. Magnesium glycinate for sleep, magnesium L-threonate for memory, magnesium citrate for digestion — TikTok wellness content, naturopath channels, and practitioner supplement catalogues have all made the claim that different magnesium salts deliver different targeted benefits. Walk into any pharmacy or health food store in Australia and the options span Blackmores, Nature’s Own, Swisse, BioCeuticals, and Metagenics at AUD 20–120 per month.

What does the evidence actually show? The answer depends entirely on who is asking and why. Magnesium supplementation can prepare the physiological environment for the body to function better — particularly in people who are deficient or marginal — but for healthy, well-nourished adults it provides little demonstrated benefit. The cognition claim for L-threonate, the most expensive form, is carried by a single industry-linked trial. The sleep signal is real but modest and concentrated in older adults with low dietary intake.

A. Core clinical — the AU general practice framework

Magnesium biology and the “marginal intake” problem

Magnesium is the fourth most abundant cation in the body and a cofactor in over 300 enzymatic reactions — ATP-binding, oxidative phosphorylation, glycolysis, DNA synthesis, neuromuscular conduction, vascular smooth muscle tone, parathyroid hormone secretion, and NMDA-receptor gating. Roughly 50–60% of body magnesium sits in bone, 20–30% in muscle, and only about 1% in extracellular fluid — which is why serum magnesium is a poor reflection of total-body stores.

The NHMRC Nutrient Reference Values set the recommended dietary intake (RDI) at 420 mg/day for men and 320 mg/day for women aged 31 and over. The Australian Health Survey 2011–12 found that approximately 30% of Australian adults had usual magnesium intake below the estimated average requirement, with higher rates in older women, lower socioeconomic groups, and people on restrictive diets.

That marginal-intake background is the single most important context for interpreting trial results: most positive signals in the magnesium literature are repletion effects in borderline-deplete cohorts, not genuine pharmacological effects in well-nourished individuals.

Populations at higher risk of depletion

The following groups are at clinically meaningful risk of magnesium depletion and are appropriate targets for repletion:

• Long-term PPI users (≥3 months, especially ≥1 year) — the FDA 2011 safety communication flagged symptomatic hypomagnesaemia (tetany, seizures, arrhythmia) with prolonged PPI use
• Loop and thiazide diuretic users — chronic urinary magnesium loss
• Type 2 diabetes with suboptimal control — osmotic diuresis drives renal magnesium loss; low magnesium is associated with worse glycaemic control
• Alcohol use disorder — renal wasting plus poor dietary intake
• Coeliac disease, inflammatory bowel disease, short bowel, chronic diarrhoea — impaired intestinal absorption
• Bariatric surgery — particularly Roux-en-Y gastric bypass and SADI-S
• Older adults — lower dietary intake plus reduced intestinal TRPM6 channel expression
• Pregnancy — increased demand; nocturnal leg cramps are very common

Pharmacokinetics — does the salt form matter?

The short answer is yes, but less dramatically than marketing claims suggest.

Magnesium oxide dominates cheap supplements and multivitamin labels because its elemental content per gram is high (~60%). Its fractional intestinal absorption, however, is only approximately 4% (Firoz 2001), and urinary recovery and serum AUC are consistently lower than citrate (Kappeler 2017). Most of the “350 mg magnesium” listed on a multivitamin label is never absorbed.

Magnesium citrate (~16% elemental) is water-soluble and clearly more bioavailable than oxide. At doses of 300–400 mg elemental or higher, it reliably softens stool through an osmotic mechanism — making it a useful combined supplement-laxative for older adults with constipation and marginal magnesium intake.

Magnesium glycinate / bisglycinate (~14% elemental) is chelated to glycine and absorbed additionally via the intestinal dipeptide transporter (PEPT-1). Its GI tolerability is subjectively better than citrate at equivalent elemental doses — less osmotic diarrhoea — making it the preferred choice when the target is repletion without laxative effect. Head-to-head pharmacokinetic data versus citrate are mixed; some studies show no plasma superiority.

Magnesium L-threonate (Magtein) (~8% elemental) is the most expensive option, patented by Magceutics/Neurocentria on the basis that it raises CSF magnesium in rodents. The patent holders and their licensees have conducted virtually all human trials. At AUD 60–120/month for ~144 mg elemental magnesium per day, it delivers a poor cost-per-milligram versus citrate or glycinate, and the independent evidence base for its cognition claims does not yet exist.

Topical magnesium oil and Epsom salt baths. Robust transdermal absorption data in intact human skin do not exist (Gröber 2017, Nutrients). These products are pleasant ritual but should not be relied upon for magnesium repletion.

B. Evidence appraisal — indication by indication

Indication	Evidence quality	Bottom line
Sleep — older adults with marginal intake	🟡 — 3 RCTs, n=151, all moderate–high bias risk; ~17 min sleep latency reduction	Worth a 4–8 week trial in older adults with poor intake; not a substitute for CBT-I
Sleep — young or healthy adults with good intake	🔴 — no meaningful benefit shown	Save the money; focus on sleep hygiene and CBT-I
Mild anxiety / PMS-related stress	🟡 — small effects in vulnerable populations, poor study quality	Reasonable adjunct for mild symptoms in marginal-intake adults; not for GAD or panic disorder
Depression (mild–moderate, open-label)	🟡 — Tarleton 2017: ΔPHQ-9 −6.0 in open-label crossover; not replicated in blinded RCT	Reasonable low-risk adjunct; does not replace SSRI or CBT
Cognition — Mg L-threonate / Magtein	🔴 — one industry-linked positive RCT (Liu 2016, n=44), no independent replication	Not recommended; opportunity cost is high
Constipation	🟢 — citrate and hydroxide are osmotic laxatives with decades of clinical evidence	Use citrate if constipation is the target; glycinate and threonate do not reliably produce osmotic effect
Muscle cramps — older adults, idiopathic	🔴 — Cochrane Garrison 2020: 11 RCTs, no significant benefit	Do not rely on magnesium for idiopathic nocturnal cramps; check statins, electrolytes, hydration
Muscle cramps — pregnancy	🟡 — small RCTs modestly positive; low harm at standard doses	Reasonable trial for 4–6 weeks in pregnancy; stop if no benefit
Atrial fibrillation	🟡 — benefit only in deficient or diuretic-treated patients; no benefit in replete AF	Check magnesium in AF patients on diuretics, PPIs, or with alcohol use; replete if low
ZMA (Zn + Mg aspartate + B6) for testosterone/strength	🔴 — independent Wilborn 2004 RCT: no effect on testosterone, IGF-1, or strength	Not recommended
Oxide vs organic salts for bioavailability	🟢 — organic salts absorb 2–4× better than oxide	Use citrate or glycinate for therapeutic intent

The clinical bottom line: identify likely-deplete patients, replete them specifically, and choose the form matched to the clinical goal (glycinate for sleep/anxiety in someone avoiding loose stools; citrate if constipation is also a target; neither for cognition).

C. Australian operations

TGA regulatory status. All oral magnesium supplements sold in Australia are listed (AUST L) complementary medicines under the TGA listed medicines framework. Ingredients must come from the Permissible Ingredients Determination. Only low-level health claims are permitted — the TGA does not individually assess efficacy of listed medicines. There are no AUST R registered oral magnesium supplements at therapeutic-claim level.

AUST L listing means the TGA has assessed safety and quality — not efficacy. Patients need to understand this: an AUST L number on a product is not proof the product does what it claims.

Major AU brands. Blackmores Magnesium Plus (citrate/oxide blend, ~AUD 25–40/month); Nature’s Own High Strength Magnesium (citrate, ~AUD 20–30); Swisse Ultiboost Magnesium (oxide-dominant, ~AUD 20–30); BioCeuticals UltraMuscleEze / NightX (practitioner range, ~AUD 50–70); Metagenics CalmX (practitioner range, ~AUD 55–80); Magtein-licensed L-threonate products (~AUD 60–120 for ~144 mg elemental/day).

PBS and MBS. No PBS subsidy for any oral magnesium supplement. Parenteral magnesium sulfate is PBS-listed only for hospital or specialist use (eclampsia, severe hypomagnesaemia). MBS standard consultations 23/36/44 cover assessment of fatigue, cramps, insomnia, or anxiety where magnesium is under consideration. Serum magnesium level (MBS 66506 range) is relevant where clinical depletion is suspected.

Drug interactions requiring clinical attention (per AMH):

• Separate magnesium by at least 4 hours from tetracyclines, fluoroquinolones, and oral bisphosphonates — chelation significantly reduces their absorption
• Loop and thiazide diuretics increase urinary magnesium loss — supplementation may be warranted
• PPIs reduce magnesium absorption; reduce PPI dose or supplement if symptomatic depletion develops

Renal safety. Contraindicated or use with extreme caution in eGFR below 30. Risk of progressive hypermagnesaemia (loss of deep tendon reflexes, bradyarrhythmia, hypotension, respiratory depression at high levels). Review renal function in any older patient or patient on polypharmacy before recommending supplementation.

D. Practical advice — choosing a magnesium supplement

Practical questions from patients and what the evidence shows:

“I can’t sleep — should I take magnesium?” If you are over 60, eat a poor diet, or are on a PPI or diuretic, a 4–8 week trial of magnesium glycinate 200–400 mg elemental per evening is reasonable and low-harm. It is unlikely to be transformative, and CBT-I (structured sleep restriction and stimulus control) is the evidence-based first-line for chronic insomnia — This Way Up offers a free online CBT-I programme.

“I’m anxious — will magnesium help?” It may modestly help with mild stress or PMS-related anxiety if your dietary intake is low. It is not evidence-based treatment for diagnosed anxiety disorders.

“Should I take threonate for my memory?” The evidence does not support this at AUD 60–120 per month. Until independent replications exist, this is a buyer-beware product.

“What about magnesium spray or Epsom salt baths?” Neither provides reliable magnesium repletion — transdermal absorption through intact skin is unproven. Epsom salt baths are a pleasant ritual with no therapeutic magnesium effect.

E. Special populations

Pregnancy and nocturnal leg cramps. Very common. Magnesium citrate or glycinate 300 mg elemental per day is a low-harm trial for 4–6 weeks in the third trimester. Reduce dose if significant loose stools occur. Cochrane evidence for pregnancy cramps is modest but more supportive than for older adults with idiopathic cramps.

Atrial fibrillation on diuretics or PPIs. Check serum magnesium. Oral repletion (200–400 mg elemental/day) is appropriate if magnesium is low or borderline low. This is particularly important because hypomagnesaemia lowers the threshold for atrial ectopy and can worsen AF rate control.

Type 2 diabetes. Low serum magnesium is associated with worse glycaemic control and insulin resistance. If dietary intake is poor or osmotic diuresis is significant, supplementation is a reasonable adjunct to lifestyle and pharmacotherapy.

Chronic kidney disease (eGFR below 30). Avoid oral magnesium supplementation — the kidneys cannot adequately excrete magnesium excess, creating hypermagnesaemia risk. Check serum magnesium if symptomatic.

When to escalate

Seek further assessment when:

• Symptomatic hypomagnesaemia (muscle cramps, tetany, fasciculation, cardiac ectopy, seizures) despite supplementation — check serum magnesium and treat parenterally if severe
• Magnesium below the reference range in a high-risk patient (PPI, diuretic, alcohol use disorder, bariatric surgery) — investigate cause and consider IV repletion
• AF with low serum magnesium — discuss with cardiologist regarding IV vs oral repletion
• Suspected drug interaction reducing absorption of critical medications (bisphosphonates, antibiotics)
• Pregnancy with persistent severe cramps unresponsive to oral magnesium — obstetric review

What this article is and is not

This is general health information drawing on NHMRC Nutrient Reference Values, TGA listed medicines guidance, Australian Medicines Handbook, NPS MedicineWise, and the peer-reviewed evidence base. It is not personal medical advice and does not create a doctor–patient relationship. Supplement decisions — particularly in people with kidney disease, cardiac conditions, or on the medications listed above — should be discussed with your GP first.

Consumer resources: HealthDirect — vitamins and supplements, NPS MedicineWise, Eat For Health — NHMRC nutrient reference values.

---

Sources cited

1. NHMRC Nutrient Reference Values — Magnesium
2. TGA — Listed medicines (AUST L) overview
3. Australian Medicines Handbook (AMH)
4. NPS MedicineWise — complementary medicines
5. Abbasi B et al 2012 — Magnesium for primary insomnia in elderly (J Res Med Sci)
6. Mah J & Pitre T 2021 — Oral magnesium for insomnia in older adults: SR/MA (BMC Complement Med Ther)
7. Boyle NB et al 2017 — Magnesium supplementation on anxiety/stress: SR (Nutrients)
8. Tarleton EK et al 2017 — Magnesium for depression: RCT (PLoS ONE)
9. Liu G et al 2016 — Mg-L-threonate (Magtein) for cognitive impairment (J Alzheimers Dis)
10. Garrison SR et al 2020 — Cochrane: Magnesium for skeletal muscle cramps
11. Kappeler D et al 2017 — Magnesium citrate vs oxide bioavailability: crossover RCT (BMC Nutrition)
12. Firoz M & Graber M 2001 — Bioavailability of magnesium preparations
13. Gröber U et al 2017 — Myth or reality: transdermal magnesium? (Nutrients)
14. FDA 2011 — PPI use and hypomagnesaemia safety communication
15. HealthDirect — vitamins and supplements